Reports FY24 revenue $1.139M, consensus $1.39M. “We made substantial progress in the fourth quarter of 2024, with our announcement at SUO of topline data from the Phase 3 BOND-003 Cohort C trial, as well as a successful follow-on equity offering to expand our clinical development programs and support our commercial readiness activities,” said Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology (CGON). “Looking ahead, further readouts are expected from our BOND-003 trial and the anticipated initiation of our Biologics License Application submission, as well as the announcement of topline data from CORE-008 Cohort A expected before year-end.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CGON:
- Promising Phase 3 Trial Results and Strong Market Potential Drive Buy Rating for CG Oncology
- Buy Rating for CG Oncology: Promising Phase 3 Results and Strong Safety Profile of Cretostimogene
- Buy Rating for CG Oncology Backed by Promising Phase 3 Study Results and Strong Safety Profile
- CG Oncology’s Promising Phase 3 Trial Results Revealed
- CG Oncology says 75.5% of patients achieve CR in Phase 3 study of cretostimogene